Is ABIO or MO a better dividend investment in 2026?

ABIO currently yields 11.04% with a 5% 5-year dividend growth rate. MO yields 6.27% with 4.3% growth. The better choice depends on your goal: ABIO offers higher current income.

What is the dividend yield difference between ABIO and MO?

ABIO has a forward dividend yield of 11.04% ($3.18/share annually). MO yields 6.27% ($4.20/share annually). The yield gap is 4.77 percentage points.

Home › Compare › ABIO vs MO

ABIO vs MO: Dividend Comparison 2026

ABIO yields 11.04% · MO yields 6.27%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MO wins by $36.2K in total portfolio value· pulled ahead in Year 8

INVESTMENT

TIME HORIZON10 years

ABIO

● Live price

11.04%

Share price

$28.80

Annual div

$3.18

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$41.5K

Annual income

$2,204.34

Full ABIO calculator →

Altria Group Inc.

● Live price

6.27%

Share price

$67.02

Annual div

$4.20

5Y div CAGR

22.6%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$77.7K

Annual income

$28,968.54

Full MO calculator →

Portfolio growth — ABIO vs MO

📍 MO pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ABIO	MO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ABIO + MO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ABIO pays

MO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABIO

Annual income on $10K today (after 15% tax)

$938.54/yr

After 10yr DRIP, annual income (after tax)

$1,873.69/yr

Annual income on $10K today (after 15% tax)

$532.68/yr

After 10yr DRIP, annual income (after tax)

$24,623.26/yr

At 15% tax rate, MO beats the other by $22,749.57/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABIO + MO for your $10,000?

ABIO: 50%MO: 50%

100% MO50/50100% ABIO

Portfolio after 10yr

$59.6K

Annual income

$15,586.44/yr

Blended yield

26.16%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ABIO

Analyst Ratings

Buy

Consensus: Buy

Altman Z

0.7

Piotroski

2/9

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$61.25

-8.6% upside vs current

Range: $47.00 — $68.00

Altman Z

3.2

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABIO buys

MO buys

No recent congressional trades found for ABIO or MO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricABIOMO

Forward yield	11.04% ✓	6.27%
Annual dividend / share	$3.18	$4.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	22.6% ✓
Portfolio after 10y	$41.5K	$77.7K ✓
Annual income after 10y	$2,204.34	$28,968.54 ✓
Total dividends collected	$16.5K	$72.0K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples
Analyst consensus	Buy	Buy

Year-by-year: ABIO vs MO ($10,000, DRIP)

Year	ABIO Portfolio	ABIO Income/yr	MO Portfolio	MO Income/yr	Gap
1	$11,804	$1,104.17	$10,558	$768.31	+$1.2K → ABIO
2	$13,849	$1,218.11	$11,352	$1,015.87	+$2.5K → ABIO
3	$16,154	$1,335.59	$12,482	$1,367.86	+$3.7K → ABIO
4	$18,740	$1,455.97	$14,103	$1,883.39	+$4.6K → ABIO
5	$21,631	$1,578.61	$16,472	$2,664.91	+$5.2K → ABIO
6	$24,848	$1,702.89	$20,024	$3,897.79	+$4.8K → ABIO
7	$28,415	$1,828.18	$25,537	$5,933.74	+$2.9K → ABIO
8← crossover	$32,358	$1,953.89	$34,478	$9,476.77	$2.1K → MO
9	$36,703	$2,079.45	$49,776	$16,022.63	$13.1K → MO
10	$41,476	$2,204.34	$77,699	$28,968.54	$36.2K → MO

ABIO vs MO: Complete Analysis 2026

ABIO — Stock

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Full ABIO Calculator →

MO — Consumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →

📬

Get this ABIO vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABIO vs SCHD ABIO vs JEPI ABIO vs O ABIO vs KO ABIO vs MAIN ABIO vs PM ABIO vs BTI ABIO vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.